Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$27,000.00
Evaluating Orosomucoid-like-3's protective role in the murine intestinal epithelium during colitis
FY 2024-25
Summary
Inflammatory bowel diseases (IBD), such as Crohn disease (CD) and ulcerative colitis (UC), are chronic conditions that impact the gastrointestinal tract, affecting nearly 300,000 Canadians. Although many genetic and environmental factors contribute towards IBD development, the exact causes remain unknown. While identifying novel metabolites linked with IBD, a key study characterized sphingolipids, which are a class of lipids with diverse signaling and structural roles. It found that sphingolipids that were produced by the host, as opposed to by bacteria, were highly upregulated in stool samples of UC and CD patients compared to healthy controls. Given that intestinal epithelial cells (IECs) are central to sphingolipid absorption and processing, these findings suggest that sphingolipid dysregulation in IECs may contribute to IBD pathogenesis. Interestingly, variants in ORMDL3 (Orosomucoid-like-3), a regulator of host-sphingolipid production, have also been associated with UC development, further indicating that impaired sphingolipid regulation in IECs may play a key role in the onset and progression of IBD. Despite these results however, the potential protective role of ORMDL3 during colitis has not been evaluated with animal models, especially in the context of IECs. To bridge this gap, mice with an IEC-specific knockout of Ormdl3and littermate wildtype mice will be challenged with a 12-day dextran sodium sulfate (DSS) model of colitis. Inflammation will then be assessed through cytokine analysis, fecal lipocalin-2 levels, and histological markers of inflammation and tissue damage. This study aims to uncover the role of ORMDL3 in intestinal inflammation in vivo, possibly paving the way for therapies targeting sphingolipid regulation to better manage and treat IBD.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
529989
Name
Singh Ojas
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Evaluating Orosomucoid-like-3's protective role in the murine intestinal epithelium during colitis
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cytokines; Dextran Sodium Sulfate; Histology; Immune Response; Inflammatory Bowel Disease; Intestinal Epithelium; Mouse Model; Ormdl3; Sphingolipids; Ulcerative Colitis
Abstract
Inflammatory bowel diseases (IBD), such as Crohn disease (CD) and ulcerative colitis (UC), are chronic conditions that impact the gastrointestinal tract, affecting nearly 300,000 Canadians. Although many genetic and environmental factors contribute towards IBD development, the exact causes remain unknown. While identifying novel metabolites linked with IBD, a key study characterized sphingolipids, which are a class of lipids with diverse signaling and structural roles. It found that sphingolipids that were produced by the host, as opposed to by bacteria, were highly upregulated in stool samples of UC and CD patients compared to healthy controls. Given that intestinal epithelial cells (IECs) are central to sphingolipid absorption and processing, these findings suggest that sphingolipid dysregulation in IECs may contribute to IBD pathogenesis. Interestingly, variants in ORMDL3 (Orosomucoid-like-3), a regulator of host-sphingolipid production, have also been associated with UC development, further indicating that impaired sphingolipid regulation in IECs may play a key role in the onset and progression of IBD. Despite these results however, the potential protective role of ORMDL3 during colitis has not been evaluated with animal models, especially in the context of IECs. To bridge this gap, mice with an IEC-specific knockout of Ormdl3and littermate wildtype mice will be challenged with a 12-day dextran sodium sulfate (DSS) model of colitis. Inflammation will then be assessed through cytokine analysis, fecal lipocalin-2 levels, and histological markers of inflammation and tissue damage. This study aims to uncover the role of ORMDL3 in intestinal inflammation in vivo, possibly paving the way for therapies targeting sphingolipid regulation to better manage and treat IBD.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Singh, Ojas
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~